T1	PROC 47 58	tratamiento
#1	AnnotatorNotes T1	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T2	DISO 65 86	leishmaniasis cutánea
#2	AnnotatorNotes T2	C0023283; Leishmaniasis, Cutaneous; Disease or Syndrome
T3	PROC 738 768	tratados por vía intramuscular
#3	AnnotatorNotes T3	C0812148; Medication administration: intramuscular; Therapeutic or Preventive Procedure + C0021492; Intramuscular injection; Therapeutic or Preventive Procedure
T4	PROC 158 181	tratamiento de elección
#4	AnnotatorNotes T4	C1708063; First line treatment; Therapeutic or Preventive Procedure
T5	DISO 188 209	leishmaniasis cutánea
#5	AnnotatorNotes T5	C0023283; Leishmaniasis, Cutaneous; Disease or Syndrome
T6	CHEM 216 238	antimonio pentavalente
#6	AnnotatorNotes T6	C3848565; antimony cation (5+); Pharmacologic Substance · Element, Ion, or Isotope
T7	DISO 305 321	efectos adversos
#7	AnnotatorNotes T7	C0041755; Adverse reaction to drug; Pathologic Function | C0559546; Adverse reactions; Pathologic Function | C0879626; Adverse effects; Pathologic Function
T8	PROC 380 391	tratamiento
#8	AnnotatorNotes T8	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T9	PROC 464 511	Evaluar la eficacia terapéutica y la tolerancia
#9	AnnotatorNotes T9	C3274448; Tolerability Study; Research Activity + C1707887; Efficacy Study; Research Activity
T10	CHEM 516 541	isotianato de pentamidina
#10	AnnotatorNotes T10	C0030864; pentamidine isethionate; Organic Chemical · Pharmacologic Substance
T11	PROC 549 570	ensayo clínico piloto
#11	AnnotatorNotes T11	C0031928; Pilot Projects; Research Activity + C0008976; Clinical Trials; Research Activity
T12	DISO 589 610	leishmaniasis cutánea
#12	AnnotatorNotes T12	C0023283; Leishmaniasis, Cutaneous; Disease or Syndrome
T13	DISO 1661 1680	efectos colaterales
#13	AnnotatorNotes T13	C0879626; Adverse effects; Pathologic Function
T14	CHEM 781 806	isotianato de pentamidina
#14	AnnotatorNotes T14	C0030864; pentamidine isethionate; Organic Chemical · Pharmacologic Substance
T15	PROC 853 872	seguimiento clínico
#15	AnnotatorNotes T15	C3274571; Clinical Study Follow-up; Health Care Activity
T16	DISO 1041 1049	lesiones
#16	AnnotatorNotes T16	C0221198; Lesion; Finding
T17	PROC 1085 1096	tratamiento
#17	AnnotatorNotes T17	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T18	PROC 1134 1145	tratamiento
#18	AnnotatorNotes T18	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T19	DISO 1174 1182	lesiones
#19	AnnotatorNotes T19	C0221198; Lesion; Finding
T20	PROC 1221 1232	tratamiento
#20	AnnotatorNotes T20	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T21	DISO 1256 1272	efectos adversos
#21	AnnotatorNotes T21	C0041755; Adverse reaction to drug; Pathologic Function | C0559546; Adverse reactions; Pathologic Function | C0879626; Adverse effects; Pathologic Function
T22	DISO 1300 1331	edema en el sitio de aplicación
#22	AnnotatorNotes T22	C0234936; Application site edema; Pathologic Function
T23	DISO 1333 1338	mareo
#23	AnnotatorNotes T23	C0012833; Dizziness; Sign or Symptom
T24	DISO 1341 1347	fiebre
#24	AnnotatorNotes T24	C0015967; Fever; Sign or Symptom
T25	DISO 1398 1410	hipoglucemia
#25	AnnotatorNotes T25	C0020615; Hypoglycemia; Disease or Syndrome
T26	DISO 1412 1423	hipotensión
#26	AnnotatorNotes T26	C0020649; Hypotension; Finding
T27	DISO 1427 1435	diabetes
#27	AnnotatorNotes T27	C0011849; Diabetes Mellitus; Disease or Syndrome | C1802373; Diabetes mellitus (incl subtypes); Disease or Syndrome
T28	CHEM 1525 1536	pentamidina
#28	AnnotatorNotes T28	C0030863; pentamidine; Organic Chemical · Pharmacologic Substance
T29	PROC 1545 1556	tratamiento
#29	AnnotatorNotes T29	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T30	DISO 1563 1584	leishmaniasis cutánea
#30	AnnotatorNotes T30	C0023283; Leishmaniasis, Cutaneous; Disease or Syndrome
T31	DISO 1744 1763	efectos secundarios
#31	AnnotatorNotes T31	C0041755; Adverse reaction to drug; Pathologic Function | C0559546; Adverse reactions; Pathologic Function | C0879626; Adverse effects; Pathologic Function
T32	CHEM 29 40	pentamidina
#32	AnnotatorNotes T32	C0030863; pentamidine; Organic Chemical · Pharmacologic Substance
T33	ANAT 79 86	cutánea
#33	AnnotatorNotes T33	C0011646; Dermis; Tissue | C1123023; Skin; Body System
T34	ANAT 202 209	cutánea
#34	AnnotatorNotes T34	C0011646; Dermis; Tissue | C1123023; Skin; Body System
T35	ANAT 603 610	cutánea
#35	AnnotatorNotes T35	C0011646; Dermis; Tissue | C1123023; Skin; Body System
T36	DISO 1292 1297	dolor
#36	AnnotatorNotes T36	C0030193; Pain; Sign or Symptom | C0234238; Ache; Sign or Symptom
T37	ANAT 1312 1331	sitio de aplicación
#37	AnnotatorNotes T37	C0229986; Application site; Anatomical Structure
T38	ANAT 1577 1584	cutánea
#38	AnnotatorNotes T38	C0011646; Dermis; Tissue | C1123023; Skin; Body System
T39	LIVB 101 127	Leishmania (V.) panamensis
#39	AnnotatorNotes T39	C0206741; Leishmania (Viannia) panamensis; Eukaryote
T43	LIVB 575 584	pacientes
#40	AnnotatorNotes T43	C0030705; Patients; Patient or Disabled Group
T44	LIVB 710 719	pacientes
#41	AnnotatorNotes T44	C0030705; Patients; Patient or Disabled Group
T45	Route 751 768	vía intramuscular
#42	AnnotatorNotes T45	C1556154; Intramuscular Route of Drug Administration; Functional Concept
T46	Dose 773 777	4 mg
#43	AnnotatorNotes T46	[Dose expressed in mg per Kg]
T47	Dose 835 847	cuatro dosis
T48	Duration 877 887	seis meses
T49	LIVB 912 920	paciente
#44	AnnotatorNotes T49	C0030705; Patients; Patient or Disabled Group
T50	Duration 960 974	los seis meses
T51	PHYS 1019 1027	curación
#45	AnnotatorNotes T51	C2004454; Recovery - healing process; Organism Function
T52	LIVB 1104 1113	pacientes
#46	AnnotatorNotes T52	C0030705; Patients; Patient or Disabled Group
T53	Neg_cue 1150 1152	no
T55	Neg_cue 1380 1382	No
T56	Neg_cue 1424 1426	ni
T58	Neg_cue 1724 1730	ningún
T59	LIVB 1731 1739	paciente
#47	AnnotatorNotes T59	C0030705; Patients; Patient or Disabled Group
T60	PHYS 1153 1182	cicatrización de las lesiones
#48	AnnotatorNotes T60	C0043240; Wound Healing; Organism Function
T61	LIVB 1687 1702	población civil
#49	AnnotatorNotes T61	C0680413; civilian; Population Group
T40	LIVB 625 642	L. (V) panamensis
#50	AnnotatorNotes T40	C0206741; Leishmania (Viannia) panamensis; Eukaryote
T42	Frequency 819 830	interdiario
T41	Observation 365 391	resistencia al tratamiento
#51	AnnotatorNotes T41	C3542449; Drug resistance status; Finding
T54	Duration 1050 1061	mes y medio
T57	DISO 1198 1205	recaída
#52	AnnotatorNotes T57	C2825055; Recurrence (disease attribute); Pathologic Function
T62	PROC 813 817	peso
#53	AnnotatorNotes T62	C2985231; Body Weight Measurement; Diagnostic Procedure
A1	Assertion T25 Negated
A2	Assertion T26 Negated
A3	Assertion T27 Negated
A4	Assertion T60 Negated
A5	Assertion T59 Negated
A6	Assertion T31 Negated
R1	Used_for Arg1:T32 Arg2:T1	
R2	Location_of Arg1:T33 Arg2:T2	
R3	Causes Arg1:T39 Arg2:T2	
R4	Location_of Arg1:T34 Arg2:T5	
R5	Used_for Arg1:T6 Arg2:T4	
R6	Causes Arg1:T6 Arg2:T7	
T63	Quantifier_or_Qualifier 298 304	serios
#54	AnnotatorNotes T63	C0205404; Serious; Qualitative Concept
R7	Has_Quantifier_or_Qualifier Arg1:T7 Arg2:T63	
R8	Before Arg1:T6 Arg2:T41	
R9	Experiences Arg1:T43 Arg2:T10	
R10	Experiences Arg1:T43 Arg2:T12	
R11	Location_of Arg1:T35 Arg2:T12	
R12	Causes Arg1:T40 Arg2:T12	
R13	Experiences Arg1:T44 Arg2:T3	
R14	Has_Route_or_Mode Arg1:T14 Arg2:T45	
R15	Has_Dose_or_Strength Arg1:T14 Arg2:T46	
R16	Used_for Arg1:T14 Arg2:T3	
R17	Experiences Arg1:T44 Arg2:T62	
R18	Has_Frequency Arg1:T14 Arg2:T42	
R19	Has_Dose_or_Strength Arg1:T14 Arg2:T47	
R20	Has_Duration_or_Interval Arg1:T15 Arg2:T48	
T64	PROC 942 951	evaluados
#55	AnnotatorNotes T64	C0220825; Evaluation; Health Care Activity | C1261322; Evaluation procedure; Health Care Activity
R21	Has_Duration_or_Interval Arg1:T64 Arg2:T50	
R22	Experiences Arg1:T49 Arg2:T64	
R23	Experiences Arg1:T49 Arg2:T51	
R25	Experiences Arg1:T49 Arg2:T16	
R26	Overlap Arg1:T51 Arg2:T54	
R27	After Arg1:T51 Arg2:T17	
R28	Experiences Arg1:T49 Arg2:T17	
T65	Observation 1122 1145	fallaron al tratamiento
#56	AnnotatorNotes T65	C0162643; treatment failure; Finding
R29	Experiences Arg1:T52 Arg2:T65	
R30	Experiences Arg1:T52 Arg2:T18	
R31	Negation Arg1:T53 Arg2:T60	
R33	Experiences Arg1:T52 Arg2:T60	
R34	Experiences Arg1:T52 Arg2:T19	
R35	Experiences Arg1:T52 Arg2:T57	
R36	Negation Arg1:T55 Arg2:T25	
R37	Negation Arg1:T55 Arg2:T26	
R38	Negation Arg1:T56 Arg2:T27	
R41	Location_of Arg1:T37 Arg2:T22	
T66	Quantifier_or_Qualifier 1363 1378	leve a moderada
R42	Has_Quantifier_or_Qualifier Arg1:T24 Arg2:T66	
R43	Causes Arg1:T20 Arg2:T21	
R44	Causes Arg1:T20 Arg2:T36	
R45	Causes Arg1:T20 Arg2:T22	
R46	Causes Arg1:T20 Arg2:T23	
R47	Causes Arg1:T20 Arg2:T24	
R48	Used_for Arg1:T28 Arg2:T29	
R49	Location_of Arg1:T38 Arg2:T30	
R50	Experiences Arg1:T61 Arg2:T13	
R51	Negation Arg1:T58 Arg2:T59	
R52	Experiences Arg1:T59 Arg2:T31	
T67	Observation 1237 1250	bien tolerado
T68	Quantifier_or_Qualifier 1764 1770	serios
R57	Has_Quantifier_or_Qualifier Arg1:T31 Arg2:T68	
#57	AnnotatorNotes T68	C0205404; Serious; Qualitative Concep
R24	Before Arg1:T60 Arg2:T65	
A7	Assertion T68 Negated
R32	Negation Arg1:T58 Arg2:T31	
R39	Negation Arg1:T58 Arg2:T68	
T69	CONC 1625 1640	baja frecuencia
#58	AnnotatorNotes T69	C0205213; Low frequency (qualifier value); Temporal Concept
T70	Observation 12 22	tolerancia
#59	AnnotatorNotes T67	C5684674; patient tolerated procedure well; Finding
R40	Overlap Arg1:T20 Arg2:T67	
#60	AnnotatorNotes T70	C0013220; Drug Tolerance; Finding (?)
R53	Overlap Arg1:T70 Arg2:T32	
#61	AnnotatorNotes T66	C1299392; Mild to moderate; Qualitative Concept
R54	Overlap Arg1:T41 Arg2:T8	
R55	Before Arg1:T18 Arg2:T65	
R58	Before Arg1:T19 Arg2:T60	
R56	Before Arg1:T16 Arg2:T51	
A8	Experiencer T43 Patient
A9	Experiencer T44 Patient
A10	Experiencer T49 Patient
A11	Experiencer T52 Patient
A12	Experiencer T61 Patient
A13	Experiencer T59 Patient
